PriceSensitive

Impression Healthcare (ASX:IHL) places first order for 500 CBD inhalers

Health Care
ASX:IHL
19 March 2020 14:15 (AEDT)

Sourced: Shutterstock

Impression Healthcare (IHL) has placed its first order for 500 cannabidiol pressurised metered dose inhalers from Entourage Therapeutics.

Entourage has granted the medicinal cannabis company exclusivity over its product to be sold in Australia under the Special Access Scheme. The order is expected to generate around $125,000 in revenue.

“We’re delighted to be the first mover in offering a CBD inhalation administration device to the Australian medicinal cannabis market. We predict that CBD inhalers will become the preferred delivery method for many patients,” Impression CEO and Managing Director Joel Latham said.

As there are currently no other suppliers of pressurised metered dose inhalers (PMDIs) in Australia, Impression Healthcare considers this order to be highly significant.

Pressurised metered dose inhalers are a safe and effective delivery system for CBD whilst avoiding the dangers of smoking or vaping.

These inhalers are a preferable treatment for patients that are currently being treated with CBD oils.

CBD inhalers deliver CBD to the blood almost immediately compared to between one and four hours for oral CBD. Side effects of inhaled CBD are minimised compared to high-dosage oral CBD administration and, finally, CBD inhalers require a much lower dosage due to a having a higher bioavailability.

Additionally, it has been researched that the powerful anti-inflammatory properties of CBD may be applied to treat lung inflammation, with inhaling devices delivering CBD to the site of inflammation.

“We’re also excited at the prospect of opening new unregistered therapies for those suffering conditions associated with lung inflammation,” Joel added.

Various studies have supported the potential for CBD in treating pneumonia or acute lung injury-related inflammation experienced by patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD).

The company also forecasts some patients with COVID-19 will develop pneumonia and acute lung injury through inflammatory processes. Therefore, Impression will aim to investigate the potential of its CBD inhalers to help patients recover.

Impression Healthcare is up 8.11 per cent and shares are trading for 4 cents each at 12:55 pm AEDT.

Related News